Elevaは,稀な腎臓疾患の治療のための新薬の人間試験を開始し,新たなCFOを任命する. Eleva starts human trials for a new drug treating a rare kidney disease and appoints a new CFO.

Eleva(バイオ医薬品会社)は,新薬,CPV-104(CPV-104)を対象として,まれな腎臓疾患C3-Glomerlomaticyの治療を目指す,人間初の試験を開始した. Eleva, a biopharmaceutical company, has begun its first human trials for a new drug, CPV-104, aimed at treating C3-Glomerulopathy, a rare kidney disease. この薬は,身体の補充システム内での均衡を回復することを目的としている. The drug aims to restore balance within the body's complement system. さらに、Eleva は Donato Spota を新しい最高財務責任者に任命し、臨床試験の進行に伴う同社の財務戦略の管理を支援しています。 Additionally, Eleva has appointed Donato Spota as its new Chief Financial Officer to help manage the company's financial strategies as it progresses with its clinical studies.